Filing Flows › TriSalus Life Sciences (TLSI) › Q2 2026 › vs Q2 2025
TriSalus Life Sciences (TLSI) Q2 2026 vs Q2 2025 (year over year)
TriSalus Life Sciences's revenue rose $194K (+2%) from $11.2M in Q2 2025 to $11.4M in Q2 2026.
TriSalus Life Sciences, Q2 2026: revenue $11.4M (+2% year over year), operating margin -86.0%, net loss $9.2M, operating cash flow −$10.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $11.4M | $11.2M | $194K | +2% |
| Other income, net | $630K | −$959K | $1.6M | — |
| Net loss | $9.2M | $8.3M | $899K | +11% |
| Costs & expenses | $21.2M | $19.5M | $1.7M | +9% |
| Operating costs | $21.2M | $18.5M | $2.7M | +14% |
| Income tax | $4K | −$3K | $7K | — |
| Cost of revenue | $1.5M | $1.8M | −$294K | -16% |
| Research & development | $3.1M | $3.7M | −$533K | -15% |
| Sales & marketing | $11.4M | $7.2M | $4.3M | +59% |
| General & admin | $5.2M | $5.9M | −$751K | -13% |
| Operating cash sources | $12.9M | $9.4M | $3.5M | +37% |
| Depreciation & amortization | $136K | $165K | −$29K | -18% |
| Share-based compensation | $2.6M | $1.9M | $724K | +38% |
| Cash used in operations | $10.1M | $7.3M | $2.8M | +38% |
| Net loss absorbed | $9.2M | $8.3M | $899K | +11% |
| Working capital & other | $3.7M | $1.1M | $2.6M | +239% |
Questions
How much did TriSalus Life Sciences's revenue grow year over year in Q2 2026?
TriSalus Life Sciences's revenue rose $194K (+2%) from $11.2M in Q2 2025 to $11.4M in Q2 2026.